Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells
about
Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertensionEndothelinClinical pharmacokinetics and pharmacodynamics of the endothelin receptor antagonist macitentanEndothelin receptors and their antagonistsEndothelin@25 - new agonists, antagonists, inhibitors and emerging research frontiers: IUPHAR Review 12Pulmonary arterial hypertension in adults: novel drugs and catheter ablation techniques show promise? Systematic review on pharmacotherapy and interventional strategies.Investigation of mutual pharmacokinetic interactions between macitentan, a novel endothelin receptor antagonist, and sildenafil in healthy subjects.Macitentan for the treatment of pulmonary arterial hypertension.Distinct ETA receptor binding mode of macitentan as determined by site directed mutagenesisIncident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHINMacitentan, a Dual Endothelin Receptor Antagonist, in Combination with Temozolomide Leads to Glioblastoma Regression and Long-term Survival in MiceTreatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.Swift and Complete Healing of Digital Ulcers after Macitentan Treatment.Efficacy, safety and clinical pharmacology of macitentan in comparison to other endothelin receptor antagonists in the treatment of pulmonary arterial hypertension.Macitentan: first global approval.Current therapies for the treatment of systemic sclerosis-related pulmonary arterial hypertension: efficacy and safety.Novel and emerging therapies for pulmonary hypertension.Macitentan (Opsumit) for the treatment of pulmonary arterial hypertension.Current and advancing treatments for pulmonary arterial hypertension in childhood.Macitentan: a review of its use in patients with pulmonary arterial hypertension.Clinical pharmacology of endothelin receptor antagonists used in the treatment of pulmonary arterial hypertension.Pulmonary hypertension 2015: current definitions, terminology, and novel treatment options.Pharmacokinetic and pharmacodynamic evaluation of macitentan , a novel endothelin receptor antagonist for the treatment of pulmonary arterial hypertension.Treatment of pulmonary arterial hypertension in children.Endothelin research and the discovery of macitentan for the treatment of pulmonary arterial hypertension.New pharmacotherapy options for pulmonary arterial hypertension.Development of macitentan for the treatment of pulmonary arterial hypertension.Target-Mediated Drug Disposition Pharmacokinetic-Pharmacodynamic Model of Bosentan and Endothelin-1.Macitentan: A Review in Pulmonary Arterial Hypertension.Macitentan: An important addition to the treatment of pulmonary arterial hypertension.Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.Pharmacokinetic study of ACT-132577 in rat plasma by ultra performance liquid chromatography-tandem mass spectrometry.Macitentan in pulmonary arterial hypertension: The SERAPHIN trialComparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension.Update on novel targets and potential treatment avenues in pulmonary hypertension.Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects.The potential for macitentan, a new dual endothelin receptor antagonist, in the treatment of pulmonary arterial hypertension.The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog.Macitentan in Pulmonary Arterial Hypertension: A Focus on Combination Therapy in the SERAPHIN Trial.Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.
P2860
Q26747812-4CCA7A24-FED1-4E92-9D36-C135158A4088Q26767156-265CAD56-EAB5-498E-80CE-B401EBFC8BA9Q26851546-129D00E7-2629-463D-AFBD-5E84FE21A67DQ27023208-EA576F90-B974-4293-BF0B-E299F66C0BF1Q28246158-7FE353B0-76B8-4126-AB31-EF59A8B55586Q33810499-8E4F733D-0566-492D-A94A-60CBD73A584DQ34570893-1B493392-0CBA-4734-A307-0EC5E2FB7415Q34610092-25C2C466-CB1A-4AE1-8183-936FC3004FD0Q35256194-F65AECF0-1E88-45F7-848F-E2E5649049EAQ36332690-520D3100-118E-4F7B-ABB2-A4DF35C0D3A9Q36657607-DBDEC493-FFC3-4CDF-B2BA-5D9D977AEE70Q36705944-EDDF28CF-312F-4C94-A6B0-9119FDD7361DQ37475563-84EB5FD4-4459-4FDE-B48C-25CEC0EFA3CBQ38164816-F9DC4174-162C-4A5B-A324-C98821F882C9Q38168144-D6C894C1-78AA-4F47-817C-23CA58DF5952Q38175430-A5B5D487-7844-4584-94D7-CEA74B1A4A5EQ38176678-70D20312-F760-458A-81AA-26F6C0CE9A52Q38213794-7ACC63B0-5D7B-4D51-8A85-D94CDD573EEFQ38232339-7E78C441-391C-4744-B178-9346FE1BB56BQ38233833-0160F255-C0FA-4A96-8DBB-9481D56BFF2CQ38271119-46CBBF58-DFE8-42EF-8A55-59FBCBDDB52DQ38283873-50FCB950-4B2F-4B8D-97D3-7F93B2BDC7BDQ38325919-C25B6720-3E48-4783-8486-0185F12FB8A8Q38341953-406D60EC-9282-403E-B3AC-249202FDB050Q38559413-39233291-CFCD-4485-99C2-B95FEB12331EQ38569940-BFE103E7-074B-4292-9B1F-EF33CEBE803BQ38570060-DF451E36-B986-4CBB-A827-D87E0B01F5C2Q38731518-38991B9D-BF9D-4992-A299-4DE666678E80Q38942648-82243149-6992-4C74-A602-5283B00455B6Q40259209-5A33455B-A853-412B-9048-C9F07451266DQ40991626-84056BD3-1DC3-4BFE-8B33-FCC93C7BD6C4Q41571586-7C6CDA52-4E90-4EF9-A9D6-D5C81EAE13A2Q41773926-26E3C8C8-FA11-4952-AF2D-B0A8F4D4A277Q42248306-3685B44E-91EC-4CEB-A50F-359CFC106DCBQ42784219-629FD3D6-9B5B-4C2F-8037-7EA907315C93Q43576010-37D82894-7590-4A9B-9162-66FB1A072AF5Q44607924-ED95EAA8-9392-4ABA-86F4-1DA3783705AAQ46674601-4BC4C532-53D5-40A2-A666-3D3D44A9618EQ47245549-18C1C8D3-5488-4D7C-A298-E454AA3F61D7Q47566008-92D60609-E393-4647-A35F-1CA7703E9FFE
P2860
Slow receptor dissociation kinetics differentiate macitentan from other endothelin receptor antagonists in pulmonary arterial smooth muscle cells
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@ast
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en-gb
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@nl
type
label
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@ast
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en-gb
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@nl
prefLabel
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@ast
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en-gb
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@nl
P2093
P2860
P3181
P1433
P1476
Slow receptor dissociation kin ...... y arterial smooth muscle cells
@en
P2093
Celia Mueller Grandjean
John Gatfield
Martine Clozel
Oliver Nayler
Thomas Sasse
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0047662
P407
P577
2012-01-01T00:00:00Z